The percentage of patients experiencing at least one bleeding event in the two treatment groups was 24.9% and 17.7%, respectively.
Nende patsientide osa, kellel jälgimisperioodi jooksul esines vähemalt üks veritsus, oli ravimi rühmas 24, 9% ja platseebo rühmas 17, 7%.